Pre-treatment: Measure morning resting heart rate for 5 days Calculate average baseline Record any existing caffeine or stimulant use During treatment: Measure resting heart rate 3 times weekly during dose escalation Continue at each dose for minimum 4 weeks before increasing If resting HR exceeds baseline by more than 15 BPM, hold dose for an additional 2 weeks If resting HR exceeds 100 BPM at rest on two or more measurements, consult physician Expected timeline: Weeks 1-8: minimal heart rate change at starting doses Weeks 8-24: gradual increase of 5-10 BPM at therapeutic doses Weeks 24+: stabilization and gradual decline toward baseline This is the approach most researchers follow successfully, and it aligns with the standard retatrutide dosing protocol used in clinical trials
Established Findings Within Preclinical and Mechanistic Literature Published receptor pharmacology describes Retatrutide as a peptide with activity at GCGR, GIPR, and GLP-1R
Retatrutide side effects appear to be similar to those seen with other GLP-1 medicines such as Wegovy and Mounjaro
Systems adjust incrementally
[2] [3] GLP-1 medications reduced major adverse cardiovascular events by 20% in the SELECT trial, with benefits extending beyond weight loss alone
J., Christensen, B., Mller, N., Gillum, M
